Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone liposome + cytarabine for elderly secondary AML (prospective single-arm study)
ChiCTR2300070019Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone and cytarabine in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoint: Composite complete remission rate. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
mitoxantronecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300070019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070019.